Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Asset Writedowns and Impairment (2016 - 2025)

Apyx Medical (APYX) has disclosed Asset Writedowns and Impairment for 15 consecutive years, with $55000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment fell 46.08% year-over-year to $55000.0, compared with a TTM value of $341000.0 through Dec 2025, up 109.2%, and an annual FY2025 reading of $341000.0, up 109.2% over the prior year.
  • Asset Writedowns and Impairment was $55000.0 for Q4 2025 at Apyx Medical, down from $130000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $347000.0 in Q4 2023 and bottomed at -$142000.0 in Q1 2023.
  • Average Asset Writedowns and Impairment over 5 years is $73500.0, with a median of $54000.0 recorded in 2024.
  • The sharpest move saw Asset Writedowns and Impairment crashed 201.43% in 2023, then skyrocketed 12900.0% in 2025.
  • Year by year, Asset Writedowns and Impairment stood at $71000.0 in 2021, then plummeted by 54.93% to $32000.0 in 2022, then surged by 984.38% to $347000.0 in 2023, then crashed by 70.61% to $102000.0 in 2024, then plummeted by 46.08% to $55000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for APYX at $55000.0 in Q4 2025, $130000.0 in Q3 2025, and $128000.0 in Q2 2025.